Tiny trial tests new lead for implanted defibrillator
NCT ID NCT06592001
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new type of lead (a wire) for an implantable cardioverter-defibrillator (ICD) in 19 people who need one. The lead is placed under the breastbone to deliver a shock if the heart beats dangerously fast. The goal is to see if it is safe and works well enough to plan a larger study.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AtaCor EV-ICD Atala™ lead (implanted device)
- What this could lead to
- If successful, this could lead to a safer, more effective way to deliver life-saving shocks from an implantable defibrillator to prevent sudden cardiac death.
- What could go wrong
- This is a very small, early feasibility study with only 19 people and no control group. The device may not work as expected or could cause complications like infection or lead failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
19 people
The number who actually took part.
- Started
-
Feb 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. At least 18 years old 2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines Exclusion Criteria: 1. Participation in any concurrent clinical study without prior written approval from the Sponsor 2. Inability or unwillingness to provide informed consent to participate in the Study 3. Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit 4. Circumstances that may prevent data collection or completion of specified follow-up visits 5. Allergies to any device materials listed in the Instructions for Use (IFU) 6. Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure 7. Known history of lung disease with FEV1 \< 1.0 Liter Device Related: 8. Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.) 9. Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator 10. Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads 11. Any known need for future MRI Anatomy Related: 12. BMI ≥ 35 kg/m2 13. Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum 14. Prior sternotomy of any type, including but not limited to median, mini or clamshell 15. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium 16. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access. 17. History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure 18. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax 19. Surgically corrected congenital heart disease (not including catheter-based procedures) Cardiac Related: 20. Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy 21. NYHA IV functional class in past 90 days 22. Inotropic therapy in past 180 days 23. Known history of pericardial disease, pericarditis or mediastinitis 24. Patients with a medical condition that precludes them from undergoing defibrillation testing: * Severe aortic stenosis * Current Intracardiac LA or LV thrombus * Severe proximal three-vessel or left main coronary artery disease without revascularization * Hemodynamic instability * Unstable angina * Recent stroke or transient ischemic attack (within the last 6 months) * Known inadequate external defibrillation * LVEF \< 20% * LVEDD \>70 mm
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ventricular arrythmia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Christchurch Hospital
Christchurch, New Zealand
-
Sanatorio Italiano
Asunción, Paraguay
-
University Hospital Center Split
Split, 21000, Croatia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The heart rhythm threat hiding in heart attack wards
- Armband heart tracker takes on holter monitors
- Can a new electric pulse technique tame Post-Heart-Attack heart rhythms faster?
- AI may spot deadly heart rhythms before they strike
- Can a higher dose of heart radiation stop dangerous rhythms?
- Wearable ECG patch could unlock hidden heart risks